News & Analysis as of

Life Sciences › Pharmaceutical Industry › Drug Design

Troutman Pepper Locke

Embattled Biotechs Facing Uncertainty at the FDA Look to Collaborative Deal Structures

Troutman Pepper Locke on

Biotechs have faced several challenging years with slumping valuations and a competitive funding environment. However, the latest slew of retirements and layoffs at the FDA could present their greatest challenge yet....more

Rothwell, Figg, Ernst & Manbeck, P.C.

Alphabet Dives Further Into AI-Driven Drug Discovery

Rothwell, Figg, Ernst & Manbeck, P.C. on

Google’s parent company Alphabet announced the launch of a new company this week dedicated to applying deep learning methods to drug discovery. The new company is called Isomorphic Laboratories and will be led by Demis...more

Proskauer - The Patent Playbook

"Commercially Reasonable Efforts” Clauses in Drug Development Deals: What Level of Protection Do They Really Provide?

Proskauer - The Patent Playbook on

Pharmaceutical drug development is expensive. One recent study estimates that the median cost to develop a new drug is $985 million, while the average is $1.3 billion. And those figures appear to be on the low end of a broad...more

Hogan Lovells

Safeguarding drug development at academic institutions

Hogan Lovells on

Academic institutions and faculty engaged in developing novel drug therapies are navigating an increasingly complex compliance landscape. ...more

Hogan Lovells

Orientations du CEPS et nouvel accord-cadre, une avancée de concert sur le prix des innovations ?

Hogan Lovells on

Retour sur la lettre de mission que les Ministres de tutelle du Comité économique des produits de santé viennent d’adresser à son Président alors que le nouvel accord-cadre « médicaments » est en passe d’être publié....more

Morgan Lewis

FDA Issues More Guidance on Gene and Cell Therapy Products

Morgan Lewis on

January was a busy month for the US Food and Drug Administration’s precision medicine efforts, as the agency produced guidance on ASO drugs for patients with debilitating or life-threatening genetic disorders and guidance on...more

The Volkov Law Group

Delaware Court Increases Scrutiny of Corporate Board Oversight and Monitoring of Compliance Programs

The Volkov Law Group on

On October 1, 2019, in In re Clovis Oncology, Inc. Derivative Litigation, a Delaware Chancery Court denied a motion to dismiss the plaintiffs’ claims under the Caremark decision against individual directors for failing to...more

7 Results
 / 
View per page
Page: of 1

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
Sign up Log in
*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
- hide
- hide